Nancy Ratner

14PUBLICATIONS
59CO-AUTHORS
Molecular targetsNeurology and neuromuscular diseasesPeripheral nervous systemPredictive and prognostic markersCellular nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 02, 2026
KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.

|May 26, 2026
MAPK-dependent release of GDNF from Schwann cells mediates tumor-independent pain in neurofibromatosis 1.

|May 13, 2026
Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target.

|Oct 02, 2025
Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.

Kyle B Williams, Alex T Larsson, Bryant J Keller

|Sep 24, 2025
Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas.

Niousha Ahmari, Kwangmin Choi, Jianqiang Wu

|Mar 13, 2025
Granulocyte-Macrophage Colony Stimulating Factor Receptor Contributes to Plexiform Neurofibroma Initiation.

Jay Pundavela, Ashley Hall, Samantha Anne Dinglasan

Pageof 3

Frequent Collaborators

6 joint publications

Jianqiang Wu

5 joint publications

Jay Pundavela

4 joint publications

Eva Dombi

3 joint publications

Mi-Ok Kim